[go: up one dir, main page]

WO2010018563A3 - Compositions and methods for the prognosis of lymphoma - Google Patents

Compositions and methods for the prognosis of lymphoma Download PDF

Info

Publication number
WO2010018563A3
WO2010018563A3 PCT/IL2009/000764 IL2009000764W WO2010018563A3 WO 2010018563 A3 WO2010018563 A3 WO 2010018563A3 IL 2009000764 W IL2009000764 W IL 2009000764W WO 2010018563 A3 WO2010018563 A3 WO 2010018563A3
Authority
WO
WIPO (PCT)
Prior art keywords
prognosis
compositions
lymphoma
methods
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2009/000764
Other languages
French (fr)
Other versions
WO2010018563A2 (en
Inventor
Moshe Hoshen
Gila Lithwick Yanai
Meir Lahav
Ranit Aharonov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mor Research Applications Ltd
Rosetta Genomics Ltd
Original Assignee
Mor Research Applications Ltd
Rosetta Genomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Applications Ltd, Rosetta Genomics Ltd filed Critical Mor Research Applications Ltd
Publication of WO2010018563A2 publication Critical patent/WO2010018563A2/en
Publication of WO2010018563A3 publication Critical patent/WO2010018563A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Described herein are compositions and methods for prognosis of malignant lymphoma. The compositions are microRNA molecules associated with the prognosis of lymphoma, as well as various nucleic acid molecules relating thereto or derived thereof.
PCT/IL2009/000764 2008-08-12 2009-08-05 Compositions and methods for the prognosis of lymphoma Ceased WO2010018563A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8801508P 2008-08-12 2008-08-12
US61/088,015 2008-08-12

Publications (2)

Publication Number Publication Date
WO2010018563A2 WO2010018563A2 (en) 2010-02-18
WO2010018563A3 true WO2010018563A3 (en) 2010-04-15

Family

ID=41259376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2009/000764 Ceased WO2010018563A2 (en) 2008-08-12 2009-08-05 Compositions and methods for the prognosis of lymphoma

Country Status (1)

Country Link
WO (1) WO2010018563A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
HK1217215A1 (en) 2013-01-17 2016-12-30 Modernatx, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
EP3041948B1 (en) 2014-11-10 2019-01-09 Modernatx, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
WO2017127750A1 (en) 2016-01-22 2017-07-27 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
KR102469450B1 (en) 2016-05-18 2022-11-22 모더나티엑스, 인크. Polynucleotides Encoding Interleukin-12 (IL12) and Uses Thereof
AU2017286606A1 (en) 2016-06-14 2018-12-13 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP4484443A3 (en) 2016-06-29 2025-03-26 CRISPR Therapeutics AG Materials and methods for treatment of friedreich ataxia and other related disorders
WO2018002762A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
US11427838B2 (en) 2016-06-29 2022-08-30 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
CA3029132A1 (en) 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
JP7548696B2 (en) 2016-07-06 2024-09-10 バーテックス ファーマシューティカルズ インコーポレイテッド Materials and methods for treating pain-related disorders
RU2765874C2 (en) 2016-10-26 2022-02-04 МОДЕРНАТиЭкс, ИНК. Matrix ribonucleic acids for enhancing immune responses and their application methods
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP3576780A1 (en) 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
US11920148B2 (en) 2017-02-22 2024-03-05 Crispr Therapeutics Ag Compositions and methods for gene editing
EP3585807A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
WO2018154459A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
US11559588B2 (en) 2017-02-22 2023-01-24 Crispr Therapeutics Ag Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
US20200216857A1 (en) 2017-02-22 2020-07-09 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
MX2020002348A (en) 2017-08-31 2020-10-08 Modernatx Inc Methods of making lipid nanoparticles.
US20190153440A1 (en) 2017-11-21 2019-05-23 Casebia Therapeutics Llp Materials and methods for treatment of autosomal dominant retinitis pigmentosa
CA3084632A1 (en) 2017-12-21 2019-06-27 Crispr Therapeutics Ag Materials and methods for treatment of usher syndrome type 2a
WO2019123430A1 (en) 2017-12-21 2019-06-27 Casebia Therapeutics Llp Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
WO2019152557A1 (en) 2018-01-30 2019-08-08 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
WO2019200171A1 (en) 2018-04-11 2019-10-17 Modernatx, Inc. Messenger rna comprising functional rna elements
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
BR112021014845A2 (en) 2019-01-31 2021-11-03 Modernatx Inc Lipid Nanoparticle Preparation Methods
KR20210149251A (en) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. Human carbonic anhydrase 2 compositions and methods for tunable modulation
MA56539A (en) 2019-06-24 2022-04-27 Modernatx Inc ENDONUCLEASE RESISTANT MESSENGER RNA AND USES THEREOF
US20220387628A1 (en) 2019-06-24 2022-12-08 Modernatx, Inc. Messenger rna comprising functional rna elements and uses thereof
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CN112941176A (en) * 2019-12-10 2021-06-11 复旦大学 Tumor lactic acid microenvironment related non-coding small RNA molecular spectrum and application thereof
JP2023513043A (en) 2020-01-31 2023-03-30 モデルナティエックス インコーポレイテッド Method for preparing lipid nanoparticles
CN116710079A (en) 2020-07-24 2023-09-05 斯特兰德生物科技公司 Lipid nanoparticles comprising modified nucleotides
KR20230167008A (en) 2020-08-06 2023-12-07 모더나티엑스, 인크. Method for producing lipid nanoparticles
US20240166707A1 (en) 2021-01-08 2024-05-23 Strand Therapeutics Inc. Expression constructs and uses thereof
WO2022233880A1 (en) 2021-05-03 2022-11-10 Curevac Ag Improved nucleic acid sequence for cell type specific expression
AU2023227443A1 (en) 2022-03-01 2024-10-10 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
JP2025516226A (en) 2022-04-26 2025-05-27 ストランド セラピューティクス インコーポレイテッド Lipid nanoparticles containing venezuelan equine encephalitis (vee) replicon and uses thereof
EP4561546A1 (en) 2022-07-29 2025-06-04 ModernaTX, Inc. Lipid nanoparticle compositions comprising surface lipid derivatives and related uses
EP4561547A1 (en) 2022-07-29 2025-06-04 ModernaTX, Inc. Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
WO2024026475A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
CN121079317A (en) 2023-04-28 2025-12-05 深圳深信生物科技有限公司 Modified delivery vehicles and uses thereof
WO2024259373A1 (en) 2023-06-14 2024-12-19 Modernatx, Inc. Compounds and compositions for delivery of therapeutic agents
WO2025160381A1 (en) 2024-01-26 2025-07-31 Modernatx, Inc. Methods of preparing lipid nanoparticles
WO2025166202A1 (en) 2024-01-31 2025-08-07 Modernatx, Inc. Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105360A1 (en) * 2004-02-09 2006-05-18 Croce Carlo M Diagnosis and treatment of cancers with microRNA located in or near cancer associated chromosomal features
EP1676914A1 (en) * 2003-09-22 2006-07-05 Aichi Prefecture Disease type of lymphoma and method of assessing prognosis
US20070072204A1 (en) * 2005-05-02 2007-03-29 Hannon Gregory J Compositions and methods for cancer diagnosis and treatment
WO2007148235A2 (en) * 2006-05-04 2007-12-27 Rosetta Genomics Ltd Cancer-related nucleic acids

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1676914A1 (en) * 2003-09-22 2006-07-05 Aichi Prefecture Disease type of lymphoma and method of assessing prognosis
US20060105360A1 (en) * 2004-02-09 2006-05-18 Croce Carlo M Diagnosis and treatment of cancers with microRNA located in or near cancer associated chromosomal features
US20070072204A1 (en) * 2005-05-02 2007-03-29 Hannon Gregory J Compositions and methods for cancer diagnosis and treatment
WO2007148235A2 (en) * 2006-05-04 2007-12-27 Rosetta Genomics Ltd Cancer-related nucleic acids

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 841A, ISSN: 0006-4971 *
BLOOD, vol. 110, no. 11, Part 1, November 2007 (2007-11-01), 49TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 08 -11, 2007, pages 1049A, ISSN: 0006-4971 *
CALIN G A ET AL: "A MICRORNA SIGNATURE ASSOCIATED WITH PROGNOSIS AND PROGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 353, no. 17, 27 October 2005 (2005-10-27), pages 1793 - 1801, XP009058593, ISSN: 1533-4406 *
CALIN GEORGE A ET AL: "MicroRNA signatures in human cancers", NATURE REVIEWS. CANCER, NATUR PUBLISHING GROUP, LONDON, GB, vol. 6, no. 11, 1 November 2006 (2006-11-01), pages 857 - 866, XP002473506, ISSN: 1474-175X *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2005 (2005-11-01), LAWRIE CHARLES H ET AL: "MicroRNA expression profiling of diffuse large B-cell lymphoma reveals differences between germinal center-like and activated B cell-like subtypes.", XP002554909, Database accession no. PREV200600185370 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2007 (2007-11-01), ROBERTUS JAN-LUKAS ET AL: "Differences in the C13orf25 miRNA cluster in non-Hodgkin lymphoma and normal B-Cell subtypes", XP002554910, Database accession no. PREV200800218858 *
EIS P S ET AL: "Accumulation of miR-155 and BIC RNA in human B cell lymphomas", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 102, no. 10, 1 March 2005 (2005-03-01), pages 3627 - 3632, XP002396794, ISSN: 0027-8424 *
HE LIN ET AL: "A microRNA polycistron as a potential human oncogene", NATURE (LONDON), vol. 435, no. 7043, June 2005 (2005-06-01), pages 828 - 833, XP002554907, ISSN: 0028-0836 *
LAWRIE CHARLES H ET AL: "Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma", BRITISH JOURNAL OF HAEMATOLOGY,, vol. 141, no. 5, 3 March 2008 (2008-03-03), pages 672 - 675, XP002545705 *
LAWRIE CHARLES H ET AL: "MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma", INTERNATIONAL JOURNAL OF CANCER, vol. 121, no. 5, September 2007 (2007-09-01), pages 1156 - 1161, XP002554905, ISSN: 0020-7136 *
OTA A ET AL: "Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 64, no. 9, 1 May 2004 (2004-05-01), pages 3087 - 3095, XP002996247, ISSN: 0008-5472 *
ROEHLE ANJA ET AL: "MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas.", BRITISH JOURNAL OF HAEMATOLOGY SEP 2008, vol. 142, no. 5, 5 June 2008 (2008-06-05), pages 732 - 744, XP002554906, ISSN: 1365-2141 *
TAGAWA HIROYUKI ET AL: "Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development", CANCER SCIENCE, vol. 98, no. 9, September 2007 (2007-09-01), pages 1482 - 1490, XP002554908, ISSN: 1347-9032 *
TANZER A ET AL: "Molecular Evolution of a MicroRNA Cluster", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 339, no. 2, 28 May 2004 (2004-05-28), pages 327 - 335, XP004506520, ISSN: 0022-2836 *

Also Published As

Publication number Publication date
WO2010018563A2 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
WO2010018563A3 (en) Compositions and methods for the prognosis of lymphoma
WO2009108866A3 (en) Microrna signatures associated with cytogenetics and prognosis in acute myeloid leukemia (aml) and uses thereof
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2010099161A8 (en) Micrornas in never-smokers and related materials and methods
WO2009108860A3 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2009108217A3 (en) Compositions comprising k-ras sirna and methods of use
WO2009061381A3 (en) Alpha-amylase variants with altered properties
WO2009153775A3 (en) Methods for distinguishing between specific types of lung cancers
WO2007139723A8 (en) Chemicallymodified oligonucleotide primers for nucleic acid amplification
WO2007148235A3 (en) Cancer-related nucleic acids
WO2010127304A3 (en) Sequencing methods
WO2010048585A3 (en) Oligomeric compounds and methods
WO2009039189A3 (en) Compositions comprising stat3 sirna and methods of use thereof
WO2008067423A3 (en) Methods of improving the introduction of dna into bacterial cells
WO2008069906A3 (en) Digital expression of gene analysis
WO2009012263A3 (en) Tissue-specific micrornas and compositions and uses thereof
WO2009108918A3 (en) Methods and systems for social networking based on nucleic acid sequences
WO2011156654A3 (en) Pathways characterization of cells
WO2008152131A3 (en) Rnai inhibition of alpha-enac expression
WO2010045384A3 (en) Short hairpin rnas for inhibition of gene expression
WO2009153774A3 (en) Compositions and methods for prognosis of ovarian cancer
WO2011160052A3 (en) Methods and compositions for sequence specific rna endonucleases
WO2009120712A3 (en) Compositions and methods for diagnosing and treating melanoma
WO2009135219A3 (en) Detecting genetic predisposition to osteoarthritis associated conditions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09787509

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09787509

Country of ref document: EP

Kind code of ref document: A2